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Brugada syndrome is associated with sudden cardiac death
in young patients. Currently guidelines recommend the use
of implantable cardioverter-deﬁbrillator (ICD) in high-risk
patients to prevent sudden cardiac death and adjunctive
therapy with quinidine in those who have recurrent ven-
tricular tachyarrhythmias to prevent electrical storm.1,2
Nevertheless, not all patients respond to quinidine, and
management of those who do not respond to the therapy is
frequently challenging. In this report, we presented the
management of a difﬁcult case of Brugada syndrome with
recurrent ventricular tachyarrhythmias that did not respond
to quinidine therapy.Case report
A 41-year-old man with a diagnosis of Brugada syndrome
and an ICD was admitted for frequent appropriate shocks. He
had ﬁrst been admitted 9 years ago with unprovoked
syncope. At that time, standard 12-lead electrocardiogram
(ECG) showed sinus rhythm, partial right bundle branch
block with coved-type ST-segment elevation, and negative
T-wave deﬂections in leads V1 and V2, compatible with type
I Brugada pattern (Figure 1A). Echocardiography, coronary
angiogram, and magnetic resonance imaging of the brain
were unremarkable. There was no family history of unex-
plained sudden death. In view of a spontaneous type I
Brugada ECG and unprovoked syncope, an ICD was
implanted. Two weeks after discharge, the patient received
2 appropriate ICD shocks (Figure 1B). Quinidine bisulfate
500 mg twice daily was therefore initiated. Despite medical
therapy, he subsequently had 2–3 appropriate ICD shocks
per year. Two months ago, quinidine was stopped owing to
abnormal liver function test. This was complicated by anKEYWORDS Brugada syndrome; Long QT syndrome; Genetic analysis;
Quinidine; Mexiletine
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leading to the current admission.
On admission, he was found to have frequent premature
ventricular complexes (PVCs) of right ventricular outﬂow
tract origin (Figure 1C). Frequent runs of torsades de pointes
initiated by a long–short sequence secondary to ventricular
bigeminy were also documented (Figure 1D). He was treated
with intravenous isoproterenol infusion and high-rate atrial
pacing that suppressed the arrhythmia. Careful review of his
initial 12-lead ECG 9 years ago revealed that in addition to
the type I Brugada pattern, there was a prolonged corrected
QT (QTc) interval of 493 msec with late peaking of T wave
(Figure 1A), suggestive of a mixed Brugada and long QT
phenotype. Subsequent genetic analysis revealed 2 previ-
ously reported missense mutations in the SCN5A, the gene
encoding Nav1.5, the α-subunit of the cardiac sodium
channel (Figure 2A–C). The ﬁrst mutation was identiﬁed
in exon 20, which was a substitution of arginine by
glutamine at codon 1192 (R1192Q) previously reported in
patients with Brugada syndrome (Figure 2A) and long QT
syndrome (LQTS).3,4 The second mutation was identiﬁed in
exon 28, which was a substitution of glutamic acid by lysine
at codon 1784 (E1784K)5 previously reported to be asso-
ciated with the Brugada and long QT overlap syndrome
(Figure 2B). Genetic analysis of the SCN5A gene of the
patient’s son and daughter showed that one carried the
R1192Q mutation and the other carried the E1784K muta-
tion. Both of them were found to have prolonged QTc but no
Brugada phenotype on resting ECG.
Although the resting ECG exhibited features of both
Brugada and LQTS, the clinical ventricular tachyarrhyth-
mia was typical of LQTS with torsades de pointes initiated
by a long–short sequence. Based on his genetic testing
result and clinical manifestation, a therapeutic trial of
mexiletine, a class Ib antiarrhythmic drug that blocks the
late sodium current, was attempted.1 The effects of
mexiletine on the QTc interval were assessed at an
identical atrial paced rate of 70 beats per minute and
conﬁrmed a shortening of QTc from 480 msec to 438 msec
(Figure 3A). After the patient started mexiletine, torsades
de pointes were completely abolished and the patient was
discharged from the hospital.pen access article under the CC BY-NC-ND license
http://dx.doi.org/10.1016/j.hrcr.2016.07.002
KEY TEACHING POINTS
 Brugada and long QT overlap syndrome is a special
entity with clinical and electrophysiological
features of both conditions.
 Prolonged corrected QT is difﬁcult to be
appreciated in patients with type I Brugada
electrocardiogram.
 Genetic analysis in patients with inherited
arrhythmias helps conﬁrm the diagnosis and guide
medical decision.
487Hai et al Brugada and Long QT SyndromeDuring subsequent follow-up at 1 month, our patient had
no further ICD shocks but persistent frequent PVCs. To
prevent recurrence of ventricular tachyarrhythmias in the
future, we elected to ablate the triggering PVC. After
ablation of the clinical PVC at the anterior right ventricular
outﬂow tract, a second PVC emerged and was ablated at the
subpulmonary valvular region. This was followed by the
emergence of a third PVC that originated from the anterior
right ventricular Purkinje network. After ablation of the third
PVC, no more new PVCs were seen (Figure 3B). The patient
was discharged with mexiletine 150 mg twice daily and
remained free from ICD shocks for 2 years.Discussion
We present a challenging case of Brugada and long QT
overlap syndrome that resulted from a compound hetero-
zygosity of R1192Q and E1784K mutations. Despite
implantation of an ICD to prevent sudden cardiac death,
the frequent ICD shocks signiﬁcantly impaired the quality of
life of our patient, necessitating adjunctive therapy to reduce
the burden of ventricular tachyarrhythmias.
To date, more than 100 mutations within the SCN5A gene
have been identiﬁed to be responsible for Brugada syn-
drome. Based on the results of a canine wedge preparation
experiment, Yan and Antzelevitch6 proposed that the ven-
tricular tachyarrhythmia in Brugada syndrome was the result
of a phase 2 reentry secondary to reduced inward sodium
current (INa), due to loss-of-function SCN5A mutations, and
subsequent unopposed transient outward current (Ito), partic-
ularly at the right ventricular outﬂow tract. Later, electro-
physiological evidence supported a conduction abnormality
as the culprit of the disease pathogenesis. Despite ongoing
debate about the pathogenetic mechanism of Brugada
syndrome,7 quinidine, a class Ia antiarrhythmic drug with
prominent Ito blocking property, has been demonstrated in anobservational cohort to reduce inducibility of ventricular
ﬁbrillation and suppress spontaneous ventricular tachyar-
rhythmias in affected patients.8 Indeed, quinidine has been
recommended as a class IIa therapy in the latest guideline for
patients with Brugada syndrome who refuse ICD, who are
contraindicated for ICD, or who have electrical storms.1,2
Nonetheless, this drug appeared to be suboptimal in prevent-
ing ventricular tachyarrhythmias in our patient. In our case,
although the age of diagnosis and the resting ECG features
were suggestive of Brugada syndrome, the hallmark long–
short initiating sequence leading to torsades de pointes was
typical of that of LQTS. Genetic analysis found 2 interesting
mutations in our patient. The ﬁrst mutation, R1192Q, has
been shown to destabilize inactivation of the sodium current
but have no effects on steady-state activation.3,4 The second
mutation, E1784K, has been reported to cause concomitant
reduction in the peak sodium current (loss-of-function) and
persistent (late) inward sodium current (gain-of-function).5
Genetic testing of his children conﬁrmed that he was a
compound heterozygote in Trans. In patients with such
mutations, the IK-blocking property of quinidine may pro-
long their QTc interval and precipitate ventricular tachyar-
rhythmias. In a stark contrast, mexiletine, which blocks the
late sodium current, has been shown to effectively shorten
the QTc interval and reduce life-threatening ventricular
tachyarrhythmias in patients with gain-of-function mutations
in the SCN5A. In our case, the use of mexiletine, as guided by
his typical manifestation of LQTS and genetic testing result,
effectively shortened his QTc interval and completely
abolished torsades de pointes.9
Despite temporary suppression of recurrent ICD
shocks, the persistent frequent PVCs may serve as a
trigger for recurrent ventricular tachyarrhythmias at times
of inadvertent QTc prolongation in the future. As a result,
we elected to perform radiofrequency ablation for our
patient. During the procedure, consecutive PVCs origi-
nating from the right ventricular outﬂow tract continued
to emerge until ablation was performed at the anterior
right ventricular Purkinje network. This is consistent with
the ﬁndings of the original paper on ventricular ﬁbrilla-
tion ablation by Haissaguerre et al,10 who showed that
PVCs originating from the right ventricular outﬂow tract
and right ventricular Purkinje network trigger ventricular
ﬁbrillation in some patients with Brugada syndrome. It is
possible that frequent PVCs associated with Brugada
syndrome serve as a trigger of torsades de pointes in the
setting of prolonged QTc. The combined therapy of
mexiletine and radiofrequency ablation successfully
prevented recurrent ventricular tachyarrhythmias in our
patient.
Figure 1 A: Standard 12-lead electrocardiogram (ECG) showing partial right bundle branch block with a coved ST-segment elevation and negative T-wave
deﬂections in leads V1 and V2, compatible with type I Brugada pattern; the corrected QT (QTc) interval was 493 msec. B: The stored ECGs showed an episode of
ventricular ﬁbrillation/tachycardia, triggering an implantable cardioverter-deﬁbrillator shock. C: Standard 12-lead ECG showing frequent premature ventricular
complexes of right ventricular outﬂow tract origin. D: In-hospital telemetry recording showing an episode of torsades de pointes initiated by a long–short
sequence of ventricular bigeminy (asterisk).
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Figure 2 The sequence chromatogram of the 2 mutations: R1192Q (A) and E1784K (B) in SCN5A, the gene encoding Nav1.5, the α-subunit of the cardiac
sodium channel. C: Schematic representation of the primary structure of α-subunit of the cardiac sodium channel with locations of 2 SCN5A mutations.
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Figure 3 A: The effects of mexiletine (150 mg) on the corrected QT
interval during atrial paced rate of 70 beats per minute. B: Premature
ventricular complexes ablated sequentially at the anterior right ventricular
outﬂow tract, subpulmonary valvular region, and anterior right ventricular
wall. Purkinje potentials were seen at the ﬁnal ablation site.
Heart Rhythm Case Reports, Vol 2, No 6, November 2016490Conclusion
The presence of prolonged QTc in patients with type I
Brugada ECG is easily overlooked because of the prominentcoved-type ST elevation. Management of Brugada and
long QT overlap syndrome is challenging because of the
different electrophysiological basis of the 2 diseases. Our
case demonstrated the importance of genetic testing in
conﬁrming an inherited arrhythmia and guiding medical
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